PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Molocea, C.-E. ; Tsokanos, F.-F. ; Herzig, S.

Exploiting common aspects of obesity and cancer cachexia for future therapeutic strategies.

Curr. Opin. Pharmacol. 53, 101-116 (2020)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Obesity and cancer cachexia are diseases at opposite ends of the BMI. However, despite the apparent dichotomy, these pathologies share some common underlying mechanisms that lead to profound metabolic perturbations. Insulin resistance, adipose tissue lipolysis, skeletal muscle atrophy and systemic inflammation are key players in both diseases. Several strategies for pharmacological treatments have been employed in obesity and cancer cachexia but demonstrated only limited effects. Therefore, there is still a need to develop novel, more effective strategies. In this review we summarize existing therapies and discuss potential novel strategies that could arise by bridging common aspects between obesity and cachexia. We discuss the potential role of macrophage manipulation and the modulation of inflammation by targeting Nuclear Receptors (NRs) as potential novel therapeutic strategies.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
4.807
1.233
4
4
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Necrosis-factor-alpha; Adipose-tissue Inflammation; Type-2 Diabetes-mellitus; Cell Lung-cancer; Double-blind; Skeletal-muscle; Tnf-alpha; Insulin Sensitivity; Ppar-gamma; Antibody Treatment
Sprache
Veröffentlichungsjahr 2020
HGF-Berichtsjahr 2020
ISSN (print) / ISBN 1471-4892
e-ISSN 1471-4973
Zeitschrift Current opinion in pharmacology
Quellenangaben Band: 53, Heft: , Seiten: 101-116 Artikelnummer: , Supplement: ,
Verlag Elsevier
Verlagsort London
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Cancer (IDC)
POF Topic(s) 90000 - German Center for Diabetes Research
30201 - Metabolic Health
Forschungsfeld(er) Helmholtz Diabetes Center
PSP-Element(e) G-501900-251
G-502500-001
G-501900-253
Förderungen Deutsche Forschungsgemeinschaft DFG
Helmholtz Future Topic Aging and Metabolic Reprogramming (AMPro)
DOI 10.1016/j.coph.2020.07.006
WOS ID WOS:000591504200014
Scopus ID 85090047984
PubMed ID 32871469
Erfassungsdatum 2020-10-26
[➜Korrektur melden]